Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Am J Hypertens. 2014 Feb;27(2):199-206. doi: 10.1093/ajh/hpt212. Epub 2013 Nov 18.
We sought to determine the incidence of newly diagnosed diabetes in treated elderly hypertensive patients and the prognostic impact of diabetes on long-term survival.
The Second Australian National Blood Pressure (ANBP2) study randomized 6,083 hypertensive patients aged 65-84 years to angiotensin-converting enzyme inhibitor (ACEI) or thiazide diuretic-based therapy and followed them for a median of 4.1 years. Long-term survival was determined in 5,678 patients over an additional median of 6.9 years after ANBP2 (post-trial).
After ANBP2, the cohort was classified into preexisting (7.2%), newly diagnosed (5.6%), and no diabetes (87.2%) groups. A 44% higher incidence of newly diagnosed diabetes was observed in patients randomized to thiazide diuretic compared with ACEI-based treatment. The other predictors of newly diagnosed diabetes were having a higher body mass index, having a higher random blood glucose, and living in a regional location compared to major cities (a geographical classification based on accessibility) at study entry. After completion of ANBP2, compared with those with no diabetes, the preexisting diabetes group experienced higher cardiovascular (hazards ratio (HR) = 1.65; 95% confidence interval (CI) = 1.03-2.65) and all-cause mortality (HR = 1.40; 95% CI = 1.02-1.92) when adjusted for age, sex, and treatment. A similar pattern was observed after including the post-trial period for cardiovascular (HR = 1.52; 95% CI = 1.20-1.93) and all-cause mortality (HR = 1.50; 95% CI = 1.29-1.73). However, when the newly diagnosed group was compared with the no diabetes group, no significant difference was observed in cardiovascular (HR = 0.33; 95% CI = 0.11-1.05) or all-cause mortality (HR = 0.76; 95% CI = 0.47-1.23) either during the ANBP2 trial or including post-trial follow-up (cardiovascular: HR = 0.82; 95% CI = 0.58-1.17; all-cause mortality: HR = 1.04; 95% CI = 0.85-1.27).
Long-term presence of diabetes reduces survival. Compared with thiazide diuretics, ACEI-based antihypertensives may delay the development of diabetes in those at risk and thus potentially improve cardiovascular outcome in the elderly.
我们旨在确定治疗老年高血压患者中新诊断糖尿病的发生率,以及糖尿病对长期生存的预后影响。
第二项澳大利亚国家血压(ANBP2)研究将 6083 名年龄在 65-84 岁的高血压患者随机分为血管紧张素转换酶抑制剂(ACEI)或噻嗪类利尿剂治疗组,并随访中位数为 4.1 年。在 ANBP2 后(试验后)的另外中位数 6.9 年期间,对另外 5678 名患者进行了长期生存的确定。
在 ANBP2 后,队列分为预先存在的(7.2%)、新诊断的(5.6%)和无糖尿病(87.2%)组。与 ACEI 为基础的治疗相比,噻嗪类利尿剂治疗组观察到新发糖尿病的发生率高出 44%。新发糖尿病的其他预测因素是在研究入组时体重指数较高、随机血糖较高以及居住在区域位置(基于可达性的地理分类)而不是主要城市。完成 ANBP2 后,与无糖尿病患者相比,预先存在的糖尿病组经历了更高的心血管(风险比(HR)=1.65;95%置信区间(CI)=1.03-2.65)和全因死亡率(HR=1.40;95%CI=1.02-1.92),在调整年龄、性别和治疗后。当包括心血管试验后的时期(HR=1.52;95%CI=1.20-1.93)和全因死亡率(HR=1.50;95%CI=1.29-1.73)时,观察到类似的模式。然而,当将新诊断组与无糖尿病组进行比较时,在心血管(HR=0.33;95%CI=0.11-1.05)或全因死亡率(HR=0.76;95%CI=0.47-1.23)方面均未观察到显著差异,无论是在 ANBP2 试验期间还是包括试验后随访期间(心血管:HR=0.82;95%CI=0.58-1.17;全因死亡率:HR=1.04;95%CI=0.85-1.27)。
长期存在糖尿病会降低生存率。与噻嗪类利尿剂相比,基于 ACEI 的抗高血压药物可能会延迟高危人群中糖尿病的发展,从而有可能改善老年人的心血管结局。